In the latest batch of cases, the panel also found sufficient evidence to indict the president of Sanofi for violating Republic Act No. 7394 or the Consumer Act of the Philippines for manufacturing the vaccine, which posed certain risks to seronegatives, or those who have not contracted the dengue disease. The panel also found that respondent government officials were reckless when they allowed the purchase of Dengvaxia vaccine despite red flags already known to them. It also found out that clinical trials for the Dengvaxia vaccine were not yet completed when it was purchased and rolled out for use in the mass immunization program. The panel found that Sanofi indirectly admitted that Dengvaxia was a defective product due to the risk it poses to seronegatives.

Source: Philippine Daily Inquirer February 21, 2020 21:00 UTC